Varick Street

Akero Therapeutics Announces Pricing of Public Offering of Common Stock

Retrieved on: 
Wednesday, March 6, 2024
Varick Street, Attention, SAN, Jefferies Group, J.P. Morgan & Co., Prospectus, Telephone, 2nd Floor, Sale, Exercise, Equity capital markets, DSM-IV codes, Broadridge Financial Solutions, Therapy, Morgan Stanley, Madison Avenue, Patient, Evercore, Jefferies, Security (finance)

SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a public offering price of $29.00 per share.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a public offering price of $29.00 per share.
  • All of the shares in the offering are being offered by Akero Therapeutics.
  • In addition, Akero Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,650,000 shares of its common stock at the public offering price, less underwriting discounts and commissions.
  • The shares of common stock are being offered by Akero Therapeutics pursuant to an automatically effective shelf registration statement that was previously filed with the U.S. Securities and Exchange Commission (SEC).

Akero Therapeutics Announces Proposed Public Offering of Common Stock

Retrieved on: 
Monday, March 4, 2024
Varick Street, Attention, SAN, Jefferies Group, Prospectus, Telephone, 2nd Floor, Sale, Equity capital markets, DSM-IV codes, Broadridge Financial Solutions, Therapy, Morgan Stanley, Madison Avenue, Patient, Evercore, Jefferies, Security (finance)

All of the shares in the proposed offering are being offered by Akero Therapeutics.

Key Points: 
  • All of the shares in the proposed offering are being offered by Akero Therapeutics.
  • In addition, Akero Therapeutics intends to grant the underwriters a 30-day option to purchase up to an additional $45.0 million of shares of its common stock at the public offering price, less underwriting discounts and commissions.
  • The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • J.P. Morgan, Morgan Stanley, Jefferies and Evercore ISI are acting as joint book-running managers for the proposed offering.

Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Retrieved on: 
Monday, March 4, 2024
Varick Street, Attention, Mizuho, Lexington Avenue, Prospectus, Telephone, 2nd Floor, Floor, Sale, Exercise, Form, Morgan Stanley, Madison Avenue, Guggenheim, Needham & Company, Security (finance), Guggenheim Partners, Form S-3

WESTLAKE VILLAGE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the closing of its previously announced underwritten public offering of 18,157,895 shares of common stock at a public offering price of $9.50 per share, which includes 2,368,421 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock at the public offering price, less underwriting discounts and commissions.

Key Points: 
  • WESTLAKE VILLAGE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the closing of its previously announced underwritten public offering of 18,157,895 shares of common stock at a public offering price of $9.50 per share, which includes 2,368,421 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock at the public offering price, less underwriting discounts and commissions.
  • The total gross proceeds of the public offering were approximately $172.5 million, before deducting underwriting discounts and commissions and offering expenses payable by Arcutis.
  • All of the shares in the public offering were sold by Arcutis.
  • Morgan Stanley, TD Cowen, and Guggenheim Securities acted as joint lead bookrunning managers for the offering.

Absci Announces Closing of Public Offering of Common Stock Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Friday, March 1, 2024
Varick Street, Attention, Lexington Avenue, Prospectus, AI, Telephone, 2nd Floor, Sale, Form, Morgan Stanley, Cryptocurrency

The shares of common stock include 2,505,000 shares pursuant to the option granted by Absci to the underwriters, which was exercised in full.

Key Points: 
  • The shares of common stock include 2,505,000 shares pursuant to the option granted by Absci to the underwriters, which was exercised in full.
  • The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $86.4 million.
  • All of the shares in the offering were sold by Absci.
  • The shares of common stock were offered by Absci pursuant to an effective shelf registration statement on Form S-3 (File No.

Arcutis Announces Pricing of $150 Million Public Offering

Retrieved on: 
Thursday, February 29, 2024
Varick Street, Attention, Mizuho, Lexington Avenue, Psoriasis, Prospectus, Telephone, Atopic dermatitis, 2nd Floor, Floor, Sale, Form, Morgan Stanley, Madison Avenue, Guggenheim, Needham & Company, S-3, Security (finance), Guggenheim Partners

WESTLAKE VILLAGE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the pricing of its underwritten public offering of common stock.

Key Points: 
  • WESTLAKE VILLAGE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the pricing of its underwritten public offering of common stock.
  • The shares of common stock are being sold at a public offering price of $9.50 per share.
  • All shares of common stock to be sold in the offering are being offered by Arcutis.
  • The gross proceeds to Arcutis from the offering are expected to be approximately $150.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Arcutis and assuming no exercise of the underwriters’ option to purchase additional shares.

Arcutis Announces Proposed Public Offering

Retrieved on: 
Wednesday, February 28, 2024
Varick Street, Attention, Mizuho, Lexington Avenue, Prospectus, Telephone, 2nd Floor, Floor, Sale, Morgan Stanley, Madison Avenue, Guggenheim, Needham & Company, Guggenheim Partners, Security (finance)

All of the shares of common stock and pre-funded warrants in this offering are being sold by Arcutis.

Key Points: 
  • All of the shares of common stock and pre-funded warrants in this offering are being sold by Arcutis.
  • The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • In addition, Arcutis intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of shares of its common stock at the public offering price per share.
  • Morgan Stanley, TD Cowen, and Guggenheim Securities are acting as joint lead bookrunning managers for the proposed offering.

Absci Announces Pricing of Public Offering of Common Stock

Retrieved on: 
Wednesday, February 28, 2024
Varick Street, Attention, Lexington Avenue, Prospectus, AI, Telephone, 2nd Floor, Sale, Exercise, Form, Morgan Stanley, Security (finance)

VANCOUVER, Wash., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative AI drug creation company, today announced the pricing of an underwritten public offering of 16,700,000 shares of its common stock at a public offering price of $4.50 per share, before deducting underwriting discounts and commissions.

Key Points: 
  • VANCOUVER, Wash., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative AI drug creation company, today announced the pricing of an underwritten public offering of 16,700,000 shares of its common stock at a public offering price of $4.50 per share, before deducting underwriting discounts and commissions.
  • In addition, Absci has granted the underwriters a 30-day option to purchase up to an additional 2,505,000 shares of its common stock on the same terms and conditions.
  • All of the shares in the offering are to be sold by Absci.
  • The shares of common stock are being offered by Absci pursuant to an effective shelf registration statement on Form S-3 (File No.

Absci Announces Proposed Public Offering of Common Stock

Retrieved on: 
Tuesday, February 27, 2024
Varick Street, Attention, Lexington Avenue, Prospectus, AI, Telephone, 2nd Floor, Sale, Form, Morgan Stanley, Security (finance)

VANCOUVER, Wash., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative AI drug creation company, announced today that it has commenced an underwritten public offering of $75.0 million of shares of its common stock.

Key Points: 
  • VANCOUVER, Wash., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative AI drug creation company, announced today that it has commenced an underwritten public offering of $75.0 million of shares of its common stock.
  • Absci also intends to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of shares of its common stock.
  • All of the shares in the proposed offering are to be sold by Absci.
  • The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the proposed offering.

Astera Labs Announces Launch of Initial Public Offering

Retrieved on: 
Friday, March 8, 2024
Apps, Applications, Technology, Semiconductor, Other Technology, Software, Networks, Hardware, Data Management, Artificial Intelligence, Varick Street, Attention, Exchange, J.P. Morgan & Co., Prospectus, J. P. Morgan, 2nd Floor, Sale, Capital Group Companies, Morgan Stanley, Needham & Company, Roth Capital Partners, Evercore, Jefferies, Security (finance)

Astera Labs, Inc. (“Astera Labs”) today announced the launch of its initial public offering of 17,800,000 shares of its common stock.

Key Points: 
  • Astera Labs, Inc. (“Astera Labs”) today announced the launch of its initial public offering of 17,800,000 shares of its common stock.
  • The offering consists of 14,788,903 shares of common stock offered by Astera Labs and 3,011,097 shares of common stock to be sold by certain of Astera Labs’ existing stockholders.
  • In addition, the underwriters will have a 30-day option to purchase up to an additional 2,670,000 shares of common stock from Astera Labs at the initial public offering price, less underwriting discounts and commissions.
  • The initial public offering price is expected to be between $27.00 and $30.00 per share.

Sixth Street Specialty Lending, Inc. Prices Public Offering of Common Stock

Retrieved on: 
Friday, March 1, 2024
Professional Services, Finance, Varick Street, Prospectus, Investment, J. P. Morgan, RBC Capital Markets, 2nd Floor, Sale, Wells Fargo, Morgan Stanley, Keefe, Bruyette & Woods, BofA Securities, Security (finance), Goldman Sachs, Citigroup

Sixth Street Specialty Lending, Inc. (NYSE:TSLX) (“TSLX” or the “Company”) announced today that it has priced a public offering of 4,000,000 shares of its common stock for total gross proceeds of approximately $83.4 million.

Key Points: 
  • Sixth Street Specialty Lending, Inc. (NYSE:TSLX) (“TSLX” or the “Company”) announced today that it has priced a public offering of 4,000,000 shares of its common stock for total gross proceeds of approximately $83.4 million.
  • In connection with the offering, the Company has granted the underwriters for the offering an option to purchase up to an additional 600,000 shares of its common stock.
  • The offering is subject to customary closing conditions, and the shares are expected to be delivered on or about March 5, 2024.
  • TSLX expects to use the net proceeds of the offering to pay down outstanding debt under its revolving credit facility.